Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial: The Lancet Oncology

I. Vergote, G. Scambia, D.M. O'Malley, B. Van Calster, S.-Y. Park, J.M. del Campo, W. Meier, A. Bamias, N. Colombo, R.M. Wenham, A. Covens, C. Marth, M. R. Mirza, J.R. Kroep, H. Ma, C.A. Pickett, B.J. Monk, TRINOVA-3/ENGOT-ov2/GOG-3001 investigators

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial: The Lancet Oncology'. Together they form a unique fingerprint.

Medicine & Life Sciences